Novartis Raises Full Year Outlook - Presented by: The Aol. On Network

Swiss drug maker Novartis has raised its full-year outlook for 2013. It's in response to delays to a generic competitor for its blockbuster blood pressure pill Diovan. A copycat version of the drug has so far failed to be approved by U.S. regulators. The delay has bought Novartis time after losing its U.S. patent protection on Diovan last year. But it's only short term. Next year is when the impact will hit. Underlying sales and operating income rose 8 and 18 percent respectively.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
PBR $ 10.84 1.13 ▲ 11.64%
BAC $ 17.12 0.12 ▲ 0.71%
INTC $ 35.59 0.36 ▼ 1.00%
AAPL $ 116.47 0.16 ▲ 0.14%
KMI $ 39.75 0.17 ▼ 0.43%
VALE $ 9.41 0.72 ▲ 8.29%
MSFT $ 47.98 0.72 ▼ 1.48%
KMP $ 97.34 0.56 ▼ 0.57%

As of 11/21/2014, 04:15 PM
More Most Active